A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease
Mené en Chine sur 20 patientes atteintes d'une tumeur gestationnelle trophoblastique récidivante ou réfractaire, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité d'un traitement combinant camrélizumab et apatinib (durée médiane de suivi : 18,5 mois)
Gestational trophoblastic neoplasia refers to malignancies derived from placentaltrophoblasts. The principal treatment is chemotherapy. The WHO and International Federationof Obstetrics and Gynecology (FIGO) prognostic scoring system is used to triage patientsas low risk (appropriate for using single drug-regimens) or high risk (requiring multidrug-regimens)based on a-priori risk chemotherapy resistance. For patients with persistent or progressive disease, salvage therapies remain quiteeffective, such that 99% of patients with low-risk disease and 70% of those with high-riskdisease are reported to eventually develop durable complete remission. Nonetheless, there remains a fraction of patients who still either die due to diseaseor have significant morbidity from receiving multiple lines of chemotherapy.
The Lancet Oncology , 2021